FTC OKs $1.6B King, Alpharma Deal With Divestiture

Law360 (December 30, 2008, 12:00 AM EST) -- The U.S. Federal Trade Commission has allowed King Pharmaceuticals Inc. to complete its approximately $1.6 billion acquisition of rival Alpharma Inc., but it forced the sale of Alpharma’s long-acting opioid analgesic drug, Kadian, to alleviate competition concerns.

The pharmaceutical was sold to generic-drug maker Actavis, which the FTC said should allow competition between Kadian and King’s long-acting opioid, Avinza. That competition would have been lost as a result of the acquisition, the FTC maintained.

King said Tuesday that it had completed the divestiture of Kadian in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.